Literature DB >> 8324886

A reconstituted, apolipoprotein A-I containing lipoprotein reduces tumor necrosis factor release and attenuates shock in endotoxemic rabbits.

A P Hubsch1, F S Powell, P G Lerch, J E Doran.   

Abstract

A reconstituted lipoprotein, containing human apolipoprotein A-I and phosphatidylcholine (1:200, molar ratio), referred to as ApoLipo, was used prophylactically in an endotoxin shock model in anesthetized rabbits. ApoLipo was administered at a dose of 75 mg protein/kg body weight 15 min before the beginning of a slow, continuous lipopolysaccharide (LPS, endotoxin) infusion (4.17 micrograms LPS/kg/hr). During the 6 hr LPS infusion, the Control-LPS group manifested a marked increase in serum tumor necrosis factor (TNF, peak value 7.82 [2.7-11.2] ng/ml at 1 hr), and many of the pathophysiologic sequelae of endotoxin shock, including hypotension (MAP: 59 +/- 7 mmHg) and metabolic acidosis (BE: -9.9 +/- 2.7) at 3 hr, and a severe neutropenia developed rapidly (PMN count: 5 +/- 3% of baseline at 30 min). In the ApoLipo treated group, serum TNF levels did not rise during the course of LPS infusion (0.1 [0.06-0.64] ng/ml at 1 hr). Hypotension (77 +/- 2 mmHg) and acidosis (-2.7 +/- 0.4) were also significantly attenuated, and the appearance of leukopenia was delayed by 1 hr (110 +/- 12% at 30 min, but 9 +/- 2% at 2 hr). Endotoxemia in the ApoLipo treated group was reduced in comparison to controls, albeit nonsignificantly. The infusion of the same dose of phosphatidylcholine without apoA-I was significantly less efficacious.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8324886

Source DB:  PubMed          Journal:  Circ Shock        ISSN: 0092-6213


  17 in total

1.  High density lipoprotein protects against polymicrobe-induced sepsis in mice.

Authors:  Ling Guo; Junting Ai; Zhong Zheng; Deborah A Howatt; Alan Daugherty; Bin Huang; Xiang-An Li
Journal:  J Biol Chem       Date:  2013-05-08       Impact factor: 5.157

2.  Soluble CD14 acts as a shuttle in the neutralization of lipopolysaccharide (LPS) by LPS-binding protein and reconstituted high density lipoprotein.

Authors:  M M Wurfel; E Hailman; S D Wright
Journal:  J Exp Med       Date:  1995-05-01       Impact factor: 14.307

3.  Antiinflammatory effects of reconstituted high-density lipoprotein during human endotoxemia.

Authors:  D Pajkrt; J E Doran; F Koster; P G Lerch; B Arnet; T van der Poll; J W ten Cate; S J van Deventer
Journal:  J Exp Med       Date:  1996-11-01       Impact factor: 14.307

4.  Hyperlipoproteinemia enhances susceptibility to acute disseminated Candida albicans infection in low-density-lipoprotein-receptor-deficient mice.

Authors:  M G Netea; P N Demacker; N de Bont; O C Boerman; A F Stalenhoef; J W van der Meer; B J Kullberg
Journal:  Infect Immun       Date:  1997-07       Impact factor: 3.441

5.  Lipoprotein(a) inhibits lipopolysaccharide-induced tumor necrosis factor alpha production by human mononuclear cells.

Authors:  M G Netea; N de Bont; P N Demacker; B J Kullberg; L E Jacobs; T J Verver-Jansen; A F Stalenhoef; J W Van der Meer
Journal:  Infect Immun       Date:  1998-05       Impact factor: 3.441

Review 6.  Treatment of sepsis: past and future avenues.

Authors:  J D Baumgartner; T Calandra
Journal:  Drugs       Date:  1999-02       Impact factor: 9.546

Review 7.  NKT cells in sepsis.

Authors:  Briana Leung; Hobart W Harris
Journal:  Clin Dev Immunol       Date:  2010-10-04

8.  Early administration of propofol protects against endotoxin-induced acute lung injury in rats by inhibiting the TGF-beta1-Smad2 dependent pathway.

Authors:  Ju Gao; Wei-Xian Zhao; Fu-Shan Xue; Luo-Jing Zhou; Shao-qun Xu; Ning Ding
Journal:  Inflamm Res       Date:  2009-11-27       Impact factor: 4.575

Review 9.  Receptors, mediators, and mechanisms involved in bacterial sepsis and septic shock.

Authors:  Edwin S Van Amersfoort; Theo J C Van Berkel; Johan Kuiper
Journal:  Clin Microbiol Rev       Date:  2003-07       Impact factor: 26.132

10.  Role for circulating lipoproteins in protection from endotoxin toxicity.

Authors:  K R Feingold; J L Funk; A H Moser; J K Shigenaga; J H Rapp; C Grunfeld
Journal:  Infect Immun       Date:  1995-05       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.